Quantitative modeling of the effect of antigen dosage on B-cell affinity distributions in maturating germinal centers

  1. Marco Molari
  2. Klaus Eyer
  3. Jean Baudry
  4. Simona Cocco
  5. Rémi Monasson  Is a corresponding author
  1. PSL Research and CNRS, France
  2. ETH, Switzerland
  3. ESPCI, PSL Research and CNRS, France
  4. École Normale Supérieure, France

Abstract

Affinity maturation is a complex dynamical process allowing the immune system to generate antibodies capable of recognizing antigens. We introduce a model for the evolution of the distribution of affinities across the antibody population in germinal centers. The model is amenable to detailed mathematical analysis, and gives insight on the mechanisms through which antigen availability controls the rate of maturation and the expansion of the antibody population. It is also capable, upon maximum-likelihood inference of the parameters, to reproduce accurately the distributions of affinities of IgG-secreting cells we measure in mice immunized against Tetanus Toxoid under largely varying conditions (antigen dosage, delay between injections). Both model and experiments show that the average population affinity depends non-monotonically on the antigen dosage. We show that combining quantitative modelling and statistical inference is a concrete way to investigate biological processes underlying affinity maturation (such as selection permissiveness), hardly accessible through measurements.

Data availability

All the data analysed in this work are reported in the supporting excel file attached to the submission. These data come from (1) new experiments reported in the present work, and (2) previously published experiments, see Eyer et al., 2017 (referenced in manuscript). The code containing the implementation of our stochastic and deterministic model is made publicly available in the following repository: https://github.com/mmolari/affinity_maturation. The repository also includes the experimental dataset, the code to run the inference procedure and the code to reproduce the figures of the main paper (Fig. 2 to 6). Please refer to README.md file for further details.

Article and author information

Author details

  1. Marco Molari

    Laboratoire de Physique de l'École Normale Supérieure, PSL Research and CNRS, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Klaus Eyer

    Laboratory for Functional Immune Repertoire Analysis, Institute of Pharmaceutical Sciences, ETH, Zurich, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  3. Jean Baudry

    Laboratoire Colloides et Materiaux Divises (LCMD), Chemistry, Biology and Innovation (CBI), ESPCI, PSL Research and CNRS, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Simona Cocco

    Laboratoire de Physique Statistique, École Normale Supérieure, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1852-7789
  5. Rémi Monasson

    Laboratoire de Physique de l'École Normale Supérieure, PSL Research and CNRS, Paris, France
    For correspondence
    monasson@lpt.ens.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4459-0204

Funding

H2020 European Research Council (80336)

  • Klaus Eyer

Agence Nationale de la Recherche (CE30-0021-01 RBMPro)

  • Rémi Monasson

Agence Nationale de la Recherche (ANR-10-LABX-31)

  • Jean Baudry

Agence Nationale de la Recherche (ANR- 10-EQPX-34)

  • Jean Baudry

Agence Nationale de la Recherche (ANR-10-IDEX-0001-02 PSL)

  • Jean Baudry
  • Simona Cocco
  • Rémi Monasson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Armita Nourmohammad, University of Washington, United States

Ethics

Animal experimentation: Experiments using mice were validated by the CETEA ethics committee number 89 (Institut Pasteur, Paris, France) under #2013-0103, and by the French Ministry of Research under agreement #00513.02.

Version history

  1. Received: February 2, 2020
  2. Accepted: June 12, 2020
  3. Accepted Manuscript published: June 15, 2020 (version 1)
  4. Version of Record published: July 14, 2020 (version 2)

Copyright

© 2020, Molari et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,888
    views
  • 316
    downloads
  • 23
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marco Molari
  2. Klaus Eyer
  3. Jean Baudry
  4. Simona Cocco
  5. Rémi Monasson
(2020)
Quantitative modeling of the effect of antigen dosage on B-cell affinity distributions in maturating germinal centers
eLife 9:e55678.
https://doi.org/10.7554/eLife.55678

Share this article

https://doi.org/10.7554/eLife.55678

Further reading

    1. Immunology and Inflammation
    2. Medicine
    Joanna C Porter, Jamie Inshaw ... Venizelos Papayannopoulos
    Research Article

    Background:

    Prinflammatory extracellular chromatin from neutrophil extracellular traps (NETs) and other cellular sources is found in COVID-19 patients and may promote pathology. We determined whether pulmonary administration of the endonuclease dornase alfa reduced systemic inflammation by clearing extracellular chromatin.

    Methods:

    Eligible patients were randomized (3:1) to the best available care including dexamethasone (R-BAC) or to BAC with twice-daily nebulized dornase alfa (R-BAC + DA) for seven days or until discharge. A 2:1 ratio of matched contemporary controls (CC-BAC) provided additional comparators. The primary endpoint was the improvement in C-reactive protein (CRP) over time, analyzed using a repeated-measures mixed model, adjusted for baseline factors.

    Results:

    We recruited 39 evaluable participants: 30 randomized to dornase alfa (R-BAC +DA), 9 randomized to BAC (R-BAC), and included 60 CC-BAC participants. Dornase alfa was well tolerated and reduced CRP by 33% compared to the combined BAC groups (T-BAC). Least squares (LS) mean post-dexamethasone CRP fell from 101.9 mg/L to 23.23 mg/L in R-BAC +DA participants versus a 99.5 mg/L to 34.82 mg/L reduction in the T-BAC group at 7 days; p=0.01. The anti-inflammatory effect of dornase alfa was further confirmed with subgroup and sensitivity analyses on randomised participants only, mitigating potential biases associated with the use of CC-BAC participants. Dornase alfa increased live discharge rates by 63% (HR 1.63, 95% CI 1.01–2.61, p=0.03), increased lymphocyte counts (LS mean: 1.08 vs 0.87, p=0.02) and reduced circulating cf-DNA and the coagulopathy marker D-dimer (LS mean: 570.78 vs 1656.96 μg/mL, p=0.004).

    Conclusions:

    Dornase alfa reduces pathogenic inflammation in COVID-19 pneumonia, demonstrating the benefit of cost-effective therapies that target extracellular chromatin.

    Funding:

    LifeArc, Breathing Matters, The Francis Crick Institute (CRUK, Medical Research Council, Wellcome Trust).

    Clinical trial number:

    NCT04359654.

    1. Immunology and Inflammation
    Hee Young Kim, Yeon Jun Kang ... Won-Woo Lee
    Research Article

    Trained immunity is the long-term functional reprogramming of innate immune cells, which results in altered responses toward a secondary challenge. Despite indoxyl sulfate (IS) being a potent stimulus associated with chronic kidney disease (CKD)-related inflammation, its impact on trained immunity has not been explored. Here, we demonstrate that IS induces trained immunity in monocytes via epigenetic and metabolic reprogramming, resulting in augmented cytokine production. Mechanistically, the aryl hydrocarbon receptor (AhR) contributes to IS-trained immunity by enhancing the expression of arachidonic acid (AA) metabolism-related genes such as arachidonate 5-lipoxygenase (ALOX5) and ALOX5 activating protein (ALOX5AP). Inhibition of AhR during IS training suppresses the induction of IS-trained immunity. Monocytes from end-stage renal disease (ESRD) patients have increased ALOX5 expression and after 6 days training, they exhibit enhanced TNF-α and IL-6 production to lipopolysaccharide (LPS). Furthermore, healthy control-derived monocytes trained with uremic sera from ESRD patients exhibit increased production of TNF-α and IL-6. Consistently, IS-trained mice and their splenic myeloid cells had increased production of TNF-α after in vivo and ex vivo LPS stimulation compared to that of control mice. These results provide insight into the role of IS in the induction of trained immunity, which is critical during inflammatory immune responses in CKD patients.